All posts tagged "Gilead Sciences Inc."
-
247BiotechThe 3CL Secret to Pfizer’s and Todos Medical’s Success
Pfizer’s (NYSE: PFE) PAXLOVID has risen to prominence as the top COVID-19 antiviral in the world. The speed at which they rose...
-
3701BiotechPicking a Bottom in CytoDyn – Right Now
CytoDyn Inc (OTCMKT: CYDY) has been under considerable selling pressure since April and nothing seems to be able to stop it. In...
-
351BiotechCytoDyn (CYDY) Shorts Throttle Up Bashing Ahead of August Super News Cycle
Short attack timed to capitalize on consolidation and thin trading The Oregonian misquotes and twists statements taken out of context SEC case...
-
3002BiotechCytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)
CytoDyn Inc. (OTCMKTS: CYDY) announced excellent preliminary results from its Phase 1b/2 clinical trial in metastatic triple negative breast cancer...
-
337BiotechEnzolytics (ENZC) Takes on HIV Heavyweight Gilead Sciences
The cocktail of drugs given to HIV patients has been dominated by Gilead Sciences (GILD) for over a decade. They are the...
-
2.5KBiotechAikido Pharma’s (AIKI) Clinical Trial Results Continues to Validates Gilead’s $21 Billion Purchase of Immunomedics
Aikido Pharma Inc. (NASDAQ: AIKI) announced excellent phase 1 data at the annual ASCO meeting. The data was presented by Dr. Scott...
-
2.7KBiotechCytoDyn’s Adjust Course to Emphasize Philippine EUA and Long Haulers
Many CytoDyn Inc. (OTCMKTS: CYDY) shareholders have been waiting impatiently for an EUA from the US FDA and a BLA in HIV. ...
-
2943BiotechCytoDyn Saves Lives & Reduces COVID-19 Hospital Duration
6 endpoints met after full data release so shorts double down on trial failure narrative Investors in CytoDyn Inc. (OTCMKTS: CYDY) are...
-
3842BiotechWading through the STAT News FUD Attack on CytoDyn Inc. (OTCMKTS: CYDY)
CytoDyn Inc. (OTCMKTS: CYDY) announced superb top-line data in their mild to moderate COVID-19 phase 2 trial and did not disappoint; however,...
-
1.3K1BiotechCytoDyn’s (OTCMKTS: CYDY) Strong Safety Data in Mild to Moderate Smokes Gilead (NASDAQ: GILD) & Crushes Endpoint Leading to the First Potential COVID-19 Approval
CytoDyn Inc. (OTCMKTS: CYDY) announced groundbreaking safety results from its phase 2 Mild to Moderate COVID-19 trial today. The company reported ...